Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864054 · ClinicalTrials.gov registry record · Phase 1
T-Cell Therapy (ECT204) in Adults With Advanced HCC
A Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult, sponsored by Eureka Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT04864054 is a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult that is actively recruiting participants, run by Eureka Therapeutics. The registered enrollment target is 20 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT04864054, a Phase 1 study of Hepatocellular Carcinoma and Liver Cancer, Adult, is actively recruiting participants, sponsored by Eureka Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.
Conditions Studied
Interventions
- BIOLOGICAL ECT204 T cells
Study Locations (7)
California
- City of Hope - Duarte
Kansas
- Kansas University Medical Center, Principal Investigator: - Westwood
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Oregon
- Oregon Health and Sciences University - Portland
Texas
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center - Dallas
Washington
- Fred Hutchinson Cancer Center, University of Washington - Seattle
Other
- National Taiwan University Cancer Center - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04864054
The ClinicalTrials.gov registry entry for NCT04864054 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is Eureka Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ECT204 T cells is the first listed.
NCT04864054 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT04864054 about?
NCT04864054 is a clinical study titled "T-Cell Therapy (ECT204) in Adults With Advanced HCC". This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed ...
What is the current status of trial NCT04864054?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-03-11. Estimated completion is 2027-12-31.
What conditions does trial NCT04864054 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer.
What interventions are being tested in trial NCT04864054?
The interventions under investigation include: ECT204 T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04864054?
This trial is sponsored by Eureka Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04864054 being conducted?
This trial has 7 study locations across California, Kansas, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.